EBAG9 is a tumor-promoting and prognostic factor for bladder cancer

International Journal of Cancer

Volumn 124, Issue 4, 2009, Pages 799-805

  Kumagai, Jinpei ^a   Uramo, Tomohiko ^a,b,c   Ogushi, Tetsuo ^a   Takahashi, Satoru ^a   Horie Inoue, Kuniko ^c   Fujimura, Tetsuya ^a   Azuma, Kotaro ^a   Muramatsn, Masami ^c   Ouchi, Yasuyoshi ^a   Kitamura, Tadaichi ^a   Ineue, Sateshi ^a,b,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bladder cancer; EBAG9; Nude mouse; Prognosis; Proliferation

Indexed keywords

ANTIGEN; ESTROGEN; ESTROGEN RECEPTOR BINDING FRAGMENT ASSOCIATED ANTIGEN 9; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG; EBAG9 PROTEIN, HUMAN; EBAG9 PROTEIN, MOUSE; TUMOR ANTIGEN;

ADULT; AGED; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BLADDER CANCER; CARCINOGENESIS; CARCINOGENICITY; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO CULTURE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PATHOGENICITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; TUMOR PROMOTION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BLADDER TUMOR; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; NUDE MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

AGED; ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 58149457084     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23982     Document Type: Article

References (22)

1. Jemal A. Siegel R, Ward E. Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Boclmer B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG. Radical cystectomy in the treatment of invasive bladder cancer:long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
3. Watanabe T, Inoue S, Hiroi H, Orirao A, Kawashima H, Muramatsn M. Isolation of estrogen-responsive genes with a CpG island library. Mol Cell Biol 1998;18:442-9.
4. Tsuchiya F, Ikeda K, Tsutsumi O, Hiroi H, Momoeda M, Taketani Y, Muramatsn M, Inoue S. Molecular cloning and characterization of mouse EBAG9, homolog of a human cancer associated surface antigen: expression and regulation by estrogen. Biochem Biophvs Res Commun 2001;284:2-10.
5. Suzuki T, Inoue S, Kawabata W, Akahira J, Moriya T, Tsuchiya F, Ogawa S, Muramatsu M, Sasano H. EBAG9/RCAS1 in human breast carcinoma: a possible factor in endocrine-immune interactions. Br J Cancer 2001;85:1731-7.
6. Akahira JI, Aoki M, Suzuki T, Moriya T, Niikura H, Ito K, Inoue S, Okamura K, Sasano H, Yaegashi K. Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer. Br J Cancer 2004;90:2197-202.
7. Takahashi S, Urano T, Tsuchiya F, Fujimura T, Kitamura T, Ouchi Y, Muramatsu M, Inoue S. EBAG9/RCAS1 expression and its prognostic significance in prostatic cancer. Int J Cancer 2003; 106:310-15.
8. Aoki T, Inoue S, Imamura H, Fukushima J. Takahashi S, Urano T. Hasegawa K, Ogushi T, Ouchi Y, Makuuchi M. EBAG9/RCAS1 expression in hepatocellular carcinoma: correlation with tumour dedifferentiation and proliferation. Eur J Cancer 2003:39:1552-61.
9. Ogushi T, Takahashi S, Takeuchi T, Urano T, Horie-Inoue K, Kuma-gai J, Kitamura T, Ouchi Y, Muramatsu M, Inoue S. Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma. Cancer Res 2005; 65:3700-6.
10. Ikeda K, Sato M, Tsutsumi O, Tsuchiya F, Tsuneizurai M, Emi M, Imoto I, Inazawa J, Muramatsu M, Inoue S. Promoter analysis and chromosomal mapping of human EBAG9 gene. Biochem Biophys Res Comraun 2000;273:654-60.
11. Epstein JT, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urologicai Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-48.
12. Engelsberg A, Hermosilla R, Karsten U, Schuiein R, Dorken B, Rehm A. The Golgi protein RCAS1 controls cell surface expression of tumor-associated O-linked glvcan antigens. J Biol Chem 2003;278:22998-3007.
13. Sonoda K, Nakashiraa M, Kaku T, Kamura T, Nakano H, Watanabe T. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer 1996:77:1501-9.
14. Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic ceil death by the human tumor-associated antigen RCAS1. Nat Med 1999;5:938-42.
15. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-60.
16. Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A, Wilson JM, Barsoum J. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci U S A. 1998;95:14411-16.
17. Suzuki K, Nakazato H, Matsui H, Hasumi M, Shibata Y, Ito K, Fuka-bori Y, Kurokawa K, Yaraanaka H. NK cell-mediated anti-tumor immune response to human prostate cancer ceil. PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J Leukoc Biol 2001;69:531-7.
18. Dickinson AJ, Fox SB, Persad RA, Hoilyer J, Sibley GN, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994; 74:762-6.
19. Pel linen T, Ivaska J. Integrin traffic. J Ceil Sci 2006; 119:3723-31.
20. Julien S, Adriaenssens E, Ottenberg K, Furlan A, Courtand G, Vercoutter-Edouart AS, Hanisch FG, Delannoy P, Le Bourhis X. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glvcosylation pattern and enhances their tumourige-nicity. Glycobiology 2006;16:54-64.
21. Reiraer TA, Anagnostopoulos 1, Erdraann B, Lehmann I, Stein H, Daniel P, Dorken B, Rehm A. Reevaluation of the 22-1-1 antibody and its putative antigen. EBAG9/RCAS1, as a tumor marker. BMC Cancer 2005;5:47.
22. Shariat SF, Karakiewiez PT, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, Sagalowsky AI, Lotan Y. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008; 112:315-25.